CaptureSelect CH1-XL Affinity Matrix is the improved version of CaptureSelect IgG-CH1 Affinity Matrix. The specificity is the same, but it features a wider elution range (pH 3.0–4.5), increased binding capacity, and improved stability at higher pH.

CaptureSelect CH1-XL Affinity Matrix recognizes the CH1 domain of human IgG antibodies, enabling purification of all subclasses (1, 2, 3, and 4) of human IgG and Fab fragments, independent of the light-chain isotype and source material.

CaptureSelect CH1-XL Affinity Matrix features include:
• Platform approach for purification of IgGs and their Fab fragments directly from complex source materials in a single step with high purity and yield
• Elution possible at pH 4.0–4.5 with 50 mM acetate buffer
• No co-purification of overproduced free light chain due to selectivity for the CH1 domain
• No binding to bovine antibodies, so presence of fetal bovine serum is not a problem
• Excellent scalability
• Non-animal derived

View other affinity matrices for development of antibody-derived therapeutics ›

Free of animal components
CaptureSelect products contain affinity ligands based on recombinant single-domain antibody fragments (VHH) created by a proprietary technology. The VHH affinity ligand is a 12 to 15 kDa fragment comprising the three complementarity-determining regions (CDRs) that form the antigen-binding domain, efficiently produced in the yeast Saccharomyces cerevisiae by a production process free of any animal components (Animal Origin-Free).

Main characteristics:

Matrix: agarose-based, epoxide-activated
Average particle size: 65 ± 10 μm
Ligand: CaptureSelect CH1-XL affinity ligand
Ligand coupling method: epoxide coupling
Binding capacity: >15 mg/mL human Fab fragment depending on flow rate, column height, contact time. For humanized Fabs lower capacities can be observed.
Elution conditions: 100 mM glycine buffer, pH 3.0; 50 mM acetate buffer, pH 4.0–4.5
Flow rate: 50–200 cm/h (up to 2 bar)
Formulation buffer: 20% (v/v) ethanol